Actively Recruiting
Study of Cord Blood-derived IL-10IL-15 CD19-CAR NK Cell Therapy for Adults with Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-11-20
24
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and early effectiveness of cord blood-derived IL-10IL-15 CD19-CAR NK cells in adults aged 18 to 75 years with certain types of refractory or relapsed B-cell non-Hodgkin lymphoma. This early-phase trial focuses on patients who have not responded to previous treatments or have relapsed, aiming to determine the best dose and assess side effects as well as tumor response and survival outcomes. Participants receive intravenous infusions of the IL-10IL-15 CD19-CAR NK cells on days 0, 3, and 6. The trial begins with a dose-escalation phase involving 6 to 24 patients to find the recommended dose by testing three different cell doses. Following this, an additional 30 patients will receive the recommended dose in a dose-expansion phase to further evaluate safety and effectiveness. Throughout the study, participants will be closely monitored for dose-limiting toxicities during the first 28 days after treatment. Researchers will also track treatment responses, progression-free survival, overall survival, and duration of response for up to two years. Assessments include evaluating measurable tumors, organ function, and overall health status. The study team will follow safety and efficacy outcomes to better understand this treatments potential in lymphoma care.
CONDITIONS
Brief Title
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
Research Team
W
Wenbin Qian, Professor
H
Hui Liu, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here